Cabot Corporation (NYSE:CBT) Receives $89.00 Average Price Target from Brokerages

Shares of Cabot Corporation (NYSE:CBT) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $89.00.

Several brokerages have recently commented on CBT. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research note on Tuesday, May 26th. JPMorgan Chase & Co. boosted their price objective on Cabot from $70.00 to $78.00 and gave the stock an “underweight” rating in a report on Friday, August 7th. UBS Group decreased their price target on Cabot from $97.00 to $92.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Mizuho lifted their price objective on shares of Cabot from $80.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. Finally, Wall Street Zen upgraded shares of Cabot from a “hold” rating to a “buy” rating in a research note on Sunday, August 9th.

Cabot Trading Up 1.3%

Shares of CBT stock opened at $85.34 on Thursday. Cabot has a fifty-two week low of $58.33 and a fifty-two week high of $94.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.97 and a current ratio of 1.47. The stock has a 50 day simple moving average of $88.23 and a two-hundred day simple moving average of $80.75. The company has a market cap of $4.41 billion, a P/E ratio of 24.04, a PEG ratio of 10.99 and a beta of 0.84.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.66 by $0.01. The company had revenue of $982.00 million during the quarter, compared to the consensus estimate of $943.16 million. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The company’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.90 EPS. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. Research analysts forecast that Cabot will post 6.33 earnings per share for the current year.

Cabot Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.4725 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.89 annualized dividend and a yield of 2.2%. Cabot’s dividend payout ratio is 53.24%.

Insiders Place Their Bets

In related news, CEO Sean D. Keohane sold 91,923 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $86.41, for a total value of $7,943,066.43. Following the completion of the transaction, the chief executive officer directly owned 404,134 shares of the company’s stock, valued at approximately $34,921,218.94. This trade represents a 18.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cabot

Hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in Cabot during the 2nd quarter worth about $33,000. Torren Management LLC bought a new stake in shares of Cabot during the fourth quarter valued at about $26,000. Rothschild Investment LLC lifted its holdings in shares of Cabot by 170.4% in the fourth quarter. Rothschild Investment LLC now owns 411 shares of the specialty chemicals company’s stock worth $27,000 after buying an additional 259 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Cabot by 409.0% in the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after buying an additional 364 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its position in shares of Cabot by 1,606.9% in the fourth quarter. Global Retirement Partners LLC now owns 495 shares of the specialty chemicals company’s stock valued at $33,000 after acquiring an additional 466 shares during the period. 93.18% of the stock is currently owned by hedge funds and other institutional investors.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.